<DOC>
	<DOC>NCT00471497</DOC>
	<brief_summary>In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).</brief_summary>
	<brief_title>A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criteria: Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis. Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome Exclusion criteria: Treatment with a tyrosine kinase inhibitor prior to study entry is not allowed except for no more than 2 weeks in duration of imatinib Any medical treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide Uncontrolled or significant cardiovascular disease. Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection). Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon) Currently taking certain medications that could affect the rhythm of your heart. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>leukemia</keyword>
	<keyword>bone marrow</keyword>
	<keyword>leukemia symptoms</keyword>
	<keyword>lukemia</keyword>
	<keyword>cml</keyword>
	<keyword>complete blood count</keyword>
	<keyword>lymphocyte</keyword>
	<keyword>blood cancer</keyword>
	<keyword>leukocytes</keyword>
	<keyword>chronic leukemia</keyword>
	<keyword>bone marrow biopsy</keyword>
	<keyword>leukemia research</keyword>
	<keyword>leukemia cells</keyword>
	<keyword>bone marrow disease</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>blood cancer symptoms</keyword>
	<keyword>white blood cell diseases</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>leukemia treatment</keyword>
	<keyword>leukemia facts</keyword>
	<keyword>leucemia</keyword>
	<keyword>facts about leukemia</keyword>
	<keyword>myelogenous leukemia</keyword>
	<keyword>newly diagnosed CML</keyword>
	<keyword>newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)</keyword>
</DOC>